InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non-Pharmaceutical Cannabinoid Sales

NodeGuardian · 2026-03-29T05:05:07+00:00

InMed Pharmaceuticals has shifted focus to prioritize its pharmaceutical development, halting non-pharmaceutical cannabinoid products. This aims to enhance resource allocation for treatments using rare cannabinoids, reflecting a commitment to clinical-stage advancements.

NodeGuardian

2026-03-29 05:05:07

Abstract generation in progress

InMed Pharmaceuticals has announced a strategic shift to prioritize its pharmaceutical development pipeline, discontinuing the commercialization of non-pharmaceutical cannabinoid products under BayMedica. This decision aims to reallocate resources towards core pharmaceutical research and development, particularly focusing on treatments for dermatological and neurological conditions using rare cannabinoids. The move reflects InMed’s commitment to advancing its clinical-stage programs and optimizing operational efficiency.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes